Geron Corporation (GERN)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
Geron Corporation (GERN): cotización, análisis y datos
No hay datos disponibles
| Precio de compra | 1.29 |
| Capitalización de mercado | 982.98M |
| Ingresos (TTM) | 204.56M |
| Beneficio neto (TTM) | -67.61M |
| 0.59 | |
| -0.11 | |
| n/a | |
| 38.25 | |
| P/B (TTM) | 4.50 |
| P/S (TTM) | 4.81 |
| Fecha de resultados | May 6, 2026 |
| Precio de venta | 1.53 |
| Volumen | 9,118,389 |
| Volumen medio (20D) | 11,598,657 |
| Abierto | 1.57 |
| Anterior Cerrar | 1.55 |
| Rango del día | 1.50 - 1.57 |
| Rango de 52 semanas | 1.04 - 2.01 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is ...
Desempeño financiero
En 2025, los ingresos de Geron fueron 183.88M, un aumento de 138.83% en comparación con 76.99M del año anterior. Las ganancias fueron -83.5M, una disminución de -52.17%.
Estados financierosSorpresa de resultados
- Ingresos de $57.48M falla las estimaciones por $0, con 17.22% Crecimiento interanual.
- EPS de -0.02 falla las estimaciones por -0.01, con 33.33% Crecimiento interanual.
Los analistas proyectan ingresos de ... Actualizar
2 semanas hace · Simply Wall St.
Geron (GERN) Stock Looks Reasonable On Sales But Weak On ReturnsGeron stock has recovered over the past year but is still sitting on a steep decline over three years, while the valuation checks currently lean toward the shares looking inexpensive relative to funda...
2 semanas hace · Simply Wall St.
Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued NarrativeWhy Geron Stock Is Back in Focus After Fresh Guidance Geron (GERN) has drawn fresh attention after issuing 2026 earnings guidance tied to RYTELO net product revenue and releasing second quarter and ha...
3 semanas hace · Motley Fool
Geron (GERN) Q2 2026 Earnings Call TranscriptRYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.